BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

    The inhibition of IκBα phosphorylation by BAY11-7082 (10 µM) was confirmed using western blotting, and GAPDH was used as an internal reference.

    Cancer Lett, 2016, 378(2):131-41. BAY 11-7082 purchased from Selleck.

  • The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

    J Neurochem, 2018, 144(6):780-790. BAY 11-7082 purchased from Selleck.

  • Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

    The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody,40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001 compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding -irradiated cells.

    Mutation Research, 2016, 789:1-8. BAY 11-7082 purchased from Selleck.

  • Reverse transcription-quantitative polymerase chain reaction assays revealed the effect of atorvastatin on visfatin-induced inflammation. Human coronary artery endothelial cells were incubated in the absence or presence of 50 ng/ml visfatin, with or without 50 nM FK866, 50 µM BAY11-0782 or 10 µM atorvastatin, for 24 h. (A) Atorvastatin downregulated visfatin-induced IL-6 gene expression (P-values from left to right vs. control: 0.0081, 0.0045, 0.0233 and 0.0057). (B) Atorvastatin decreased visfatin-induced IL-8 gene expression (P-values from left to right vs. control: 0.0096, 0.0037, 0.0043 and 0.0031). (C) Atorvastatin downregulated visfatin-induced IL-6 release (P-values from left to right vs. control: 0.0078, 0.0022, 0.0783 and 0.0382). (D) Atorvastatin inhibited visfatin-induced IL-8 release (P-values from left to right vs. control: 0.0094, 0.0032, 0.0039 and 0.0035). Significant differences were determined using Student's t-test; *P<0.05, **P<0.01 vs. visfatin control. IL-6, interleukin-6; IL-8, interleukin-8.

    Oncol Lett, 2016, 12(2):1438-1444. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa NFT3Z4FHfW6ldHnvckBCe3OjeR?= NXiyN5JvOTEEoN88US=> M13yPVEvPSCq NUfPTFRW[WKxbHnzbIV{KEKSQTDpcoR2[2WmIIXwJJJm\3WuYYTpc44hd2ZiRl6gZY5lKE2PUD25xsA> MmG1NlU4QTd2M{e=
SiHa  MWLGeY5kfGmxbjDBd5NigQ>? M3;DdVExyqEQvF2= NFHNUnYyNjViaB?= NWTqUVdZ[WKxbHnzbIV{KEKSQTDpcoR2[2WmIIXwJJJm\3WuYYTpc44hd2ZiRl6gZY5lKE2PUD25xsA> NWnUdZdwOjV5OUe0N|c>
ARPE-19 MkHnSpVv[3Srb36gRZN{[Xl? MmH4NUDPxE1? MUewMlUhcA>? M2Lk[5N2eHC{ZYPz[ZMhXEdvaX7keYNm\MLiSVytPOKheHKxbX;0[ZIh[WO2aY\heIlwdg>? MmHxNlU2QTNyMkm=
HCT116 NWrvUFFVTnWwY4Tpc44hSXO|YYm= NYKzfpRxPSEQvF2= MUiyJIg> NYWxe5d3TE2VTx?= MUfheJRmdnWjdHXzJJNqdHmvYYLpck1qdmS3Y3XkJIRwf26{ZXf1cIF1cW:wIH;mJIN6[2yrbjDENS=> MoHyNlU1Pzl5MkO=
HMECs MkfJSpVv[3Srb36gRZN{[Xl? NGDQTYc2yqEQvF2= MkPINkBp NYDzWJlr[WKxbHnzbIV{KFSQRj5OtU1qdmS3Y3XkJHZESU1vMTDlfJBz\XO|aX;uxsA> NIXjfIEzPTF7M{GxOi=>
A549  MnTJSpVv[3Srb36gRZN{[Xl? NXX5RW1rOTEkgJpCuW0> M16xNFEzKGh? MX7zeZBxemW|c3XzJGR3dC1|IHnu[JVk\WRiYXP0bZZifGmxbjDv[kBxPjV? NGi4ToozPTF3NkiwNC=>
RAW 264.7 NX;BXZhHTnWwY4Tpc44hSXO|YYm= NF\vT2M2yqEQvF2= NH[0PIUyKGh? NIDHcoJqdmirYnn0d{BVVkZvzsGgZY5lKEmOLUGyJJA1OCCycn;keYN1cW:w MXOyOVAyQTV4Nx?=
macrophages MULGeY5kfGmxbjDBd5NigQ>? NYfoUHA6PSEEtV2= NXS2N25{OyCq NUn0PXRleGG{dHnhcIx6KGKub3Prd{B[WE[VLXnu[JVk\WRiZYjwdoV{e2mxbjDv[kBqVk:VIHHu[EBEV1hvMtMg MlfrNlQ6Pjd6OUi=
HUVECs MXXGeY5kfGmxbjDBd5NigQ>? NWHDbGcxOy1|MDFOwG0> MmnMNUBp MVzy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIH3pVk0yPD[jIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XnWVI1QDZ|OU[1
HeLa  NHG5ZWNHfW6ldHnvckBCe3OjeR?= NVPJeW1PPcLizszN M{P2UVI1KGh? MlPkSG1UVw>? MkCydoVlfWOnczD0bIUh[WO2aY\peJkhd2ZiVF7GMe6yKHC{b33veIVzyqB? NX7yZ4dKOjR4NUe3PFM>
A549 MUfGeY5kfGmxbjDBd5NigQ>? NFHHblgyOCEQvF2= M3PQbVHjiImq MYXpcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicHjvd5Bpdy2LzsrC{tEhcW5iUFGxNFMucW6oZXP0[YQh[3WudIXy[ZPDqA>? NYm0OYViOjR4MUK0PFg>
HUVEC NVu4PHhLTnWwY4Tpc44hSXO|YYm= MUCyNEDDvU1? NVHMXIo3OC53IHi= MoDMSG1UVw>? M4[xT5Bz\X[nboTzJJRp\SCrbnT1Z5Rqd25ib3[gSWFOKGW6cILld5Nqd25? M2nTNFI1PTVzMkC5
A549RT-eto MXHBdI9xfG:|aYOgRZN{[Xl? NH22O2QyOMLizszN NYXhTGZrOjRiaB?= MXfEUXNQ MWXhZ4NmdGW{YYTld{BHTVKRLX3l[IlifGWmIHHwc5B1d3Orcx?= MX2yOFU{PTB6Mx?=
THP-1  NVn5SFkzTnWwY4Tpc44hSXO|YYm= MmPBNE4yNzIEoN88US=> MYGwMlUhcA>? MVnhZpJw\2G2ZYOgWG5HNc7zIIPlZ5JmfGmxbjDhd{B4\WyuIHHzJJRp\SCrbnPy[YF{\WRic3XjdoV1cW:wIH;mJGlNNTZiYX7kJGlNNTIQsh?= NXzte41ROjR|N{i1N|Y>
SKCXCR2  NH:4WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojZNkDDvU1? MkTJOFghcA>? MUjk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJJNq\26rZnnjZY51dHl? MoLhNlQ{PzZ5NEe=
SKCXCR2  MXHGeY5kfGmxbjDBd5NigQ>? NWfIWnNTOiEEtV2= NX\rfnE{PDhiaB?= MoTUZoxw[2u|IITo[UBEYEOOMT3pcoR2[2WmIHPlcIwhcW64YYPpc44> Mny2NlQ{PzZ5NEe=
OVCXCR2 NG\3VmxHfW6ldHnvckBCe3OjeR?= M3vQZlIhyrWP NVHPSYtCPDhiaB?= MVHicI9kc3NidHjlJGNZS0xzLXnu[JVk\WRiY3XscEBqdn[jc3nvci=> MXSyOFM4Pjd2Nx?=
DSCs  NFTxbHFHfW6ldHnvckBCe3OjeR?= MnvGNk42KM7:TR?= MUGwMlUhcA>? M4O4dZJmfmW{c3XzJJRp\SCnbnjhcoNmdWWwdDDv[kBES0x{L1PDVlIh\XiycnXzd4lwdiCxZjDEV2N{KGmwZIXj[YQh[nliSVytN|M> M4faTVI1OzR2MkSw
WPs M3vqfmZ2dmO2aX;uJGF{e2G7 MkfoNlUh|ryP M3rtXVUhdWmw MYrzeZBxemW|c3XzJGFVWCCjbnSgendHKHOnY4LleIlwdg>? NUXVR5pkOjR|M{GyNFc>
A549RT-eto MoK5RZBweHSxc3nzJGF{e2G7 Ml;ZNVDDqM7:TR?= MUmyOEBp MXzhZ4NmdGW{YYTld{BHOTRiZYj0doFkfC2vZXTpZZRm\CCjcH;weI9{cXNiY3;tZolv\WRidILlZZRu\W62IIfpeIghTjF2 NInGSGszPDJ{MEeyOS=>
A549RT-eto MmO5SpVv[3Srb36gRZN{[Xl? MV6xNOKh|ryP MV2yOEBp MnP5[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDOSk3PwkJiYX7kJHAu\3EEoB?= NX;6blhQOjR{MkC3NlU>
FaDu M2r2RWZ2dmO2aX;uJGF{e2G7 M{DZSlIhcA>? MVLpcohq[mm2czDwOlUh\XiycnXzd4lwdiCjbnSgZoxw[2u|IGTOSu6yNWmwZIXj[YQhXFeLU2Sg[ZhxemW|c3nvci=> NEHOT28zPDJ{ME[yNi=>
IVD  NHfUSmlHfW6ldHnvckBCe3OjeR?= MVyxNOKh|ryP M4WyWFMh\A>? NHjafYtz\X[ncoPld{BVVkZvzsJihLNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjD0bIUh\Gm|YzDtZZRzcXhibXHjdo9ud2ynY4Xs[ZMh[WepcnXjZY4h[W6mIHPvcIxi\2WwIFnJ M2jjT|I1OTd4OEC4
IVD  M3W5U2Z2dmO2aX;uJGF{e2G7 NELoNosyOMLizszN Mn7QN{Bl Mn\uZYJzd2ejdHXzJHRPTi4QsfMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDBSGFOXFNvNDDhcoQhSUSDTWTTMVXDqA>? MUeyOFE4PjhyOB?=
iNKT NUTTUXRqTnWwY4Tpc44hSXO|YYm= MnjsNVAwOTByIN88US=> M2DDN|AvPSCq M2H6VYlvcGmkaYTzJJRp\SCrbnT1Z5Rqd25ib3[gRVJCWiCvUl7BJIFv\CCxdHjldkBn[WO2b4K= M1jJUlI1OTJ2NEWz
PC-3 M4PqcWZ2dmO2aX;uJGF{e2G7 NXW4Z3M4Oi53L{WvNVAh|ryP MYCwMlUhcA>? NFjpRmtjdG:la4OgTWdHNUmLLXnu[JVk\WRiU2TTJI1TVkFiZYjwdoV{e2mxbtMg NYLKb3Q4OjRyNUW1NlA>
THP-1  NWjIc4YzTnWwY4Tpc44hSXO|YYm= MWexNOKh|ryP NUnmTpJlOcLiaB?= MkHiZYJwdGm|aHXzJJRp\SCnZn\lZ5Qhd2ZicljTVFI4KG:wIGPSMWEhdVKQQR?= MVOyN|k{QTN7OB?=
A549 MVjGeY5kfGmxbjDBd5NigQ>? M3HvUFHDqM7:TR?= M376c|Q5KGh? M4PNSIVvcGGwY3XzJJRp\SC3cD3y[Yd2dGG2aX;uJI9nKEoQulKgZY5lKHO3YoPldZVmdnRiZHXjdoVie2ViaX6gRoF5KGW6cILld5Nqd25iaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=> M{O2eVI{QTByMEiw
A549 Mkm2RZBweHSxc3nzJGF{e2G7 MorhNeKh|ryP MkDkOFghcA>? M3y1dZJm\HWlZYOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=> NXP3PJhDOjN7MECwPFA>
NCI-N87 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\OZVExNzJyL{OwJO69VQ>? NF;LWpM3NzJ2IHi= NWrYV4Zwe3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 NWrNbI0{OjN6NE[1OFU>
AGS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljrNVAwOjBxM{Cg{txO M{XmOFYwOjRiaB?= Mnvld5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NXOxXXV[OjN6NE[1OFU>
MGC80-3 NUe3eG82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzrfVNZOTBxMkCvN|Ah|ryP M4PaPFYwOjRiaB?= M2joTJN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NUHQWGZHOjN6NE[1OFU>
HGC-27  NGjNNWVHfW6ldHnvckBCe3OjeR?= NGTOemY4NjVxMUWvN|Ah|ryP NHn5eok3KGh? MUXpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBidmRidYCtdoVofWyjdHnvckBw\iCLzsrC{tE> MmHGNlM5PDZ3NEW=
MGC80-3 NGPpcYhHfW6ldHnvckBCe3OjeR?= NYfOVIFLPy53L{G1M|MxKM7:TR?= Mmf2OkBp M33xVYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKGGwZDD1dE1z\We3bHH0bY9vKG:oIFpOvmLPuQ>? NFyyc4UzOzh2NkW0OS=>
HGC-27  NXjIOZJTSXCxcITvd4l{KEG|c3H5 M2rtflcvPS9zNT:zNEDPxE1? NF3wd4Q3KGh? NV[wO4pPcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MmD5NlM5PDZ3NEW=
HBE  M3nqfmZ2dmO2aX;uJGF{e2G7 MXmxNO69VQ>? M{m2Z|Np NWjhUnN7[WKxbHnzbIV{KHSqZTDpcoNz\WG|ZYOgc4YhUUxvNjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhS1OH M3nvZlI{QDJ2MEi5
HepG2 NHP3XY9HfW6ldHnvckBCe3OjeR?= NH;VWnUxNjNxMT:zJO69VQ>? M1fnOVQ5KGh? NVjl[JVmemWmdXPld{BKVDZvaX7keYNm\CCST16xJIV5eHKnc4Ppc44> MXSyN|c6OTh|Mx?=
THP-1 M2fJeWZ2dmO2aX;uJGF{e2G7 NH;Cd2g2KML3TR?= Mm\BNUBp MXjEUXNQ MV;pcohq[mm2czDNWGIucW6mdXPl[EBPTs78QjDhZ5RqfmG2aX;u M{jLZlI{PjN2MkG4
THP-1  MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;aUGs2KML3TR?= NIjqRpk1NzhiZB?= M{nHSWROW09? M3nKbpJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= MojGNlM3OzR{MUi=
MDM NEDUTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG1JOK2VQ>? NWfFfoJ6PC96IHS= M3LsbWROW09? M2TlOZJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= NVzCPGIzOjN4M{SyNVg>
AM NVLyfWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjGbZE2KML3TR?= NETzVYQ1NzhiZB?= NUTMcWR7TE2VTx?= MWPy[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE NGflZXAzOzZ|NEKxPC=>
RAW 264  MXzGeY5kfGmxbjDBd5NigQ>? MV:wMlIuPSEEtV2= NI\4Oog{OC94MD:5NEBucW5? M{HLVolvcGmkaYTzJJRp\SCyaH;zdIhifGG|ZTDhZ5Rqfmm2eTDv[kBRXFBzQtMg MUeyN|U4QDNyMh?=
HUVEC NV33O2J{TnWwY4Tpc44hSXO|YYm= M{[3[FExyqEQvF2= MWiwMlUhcA>? NGm0Om5FVVOR Mmm4Z492dnSncnHjeIV{KHSqZTDsc5N{KG:oIGTp[VIhdVKQQR?= NHTuTGQzOzV4M{[zNi=>
HT29 NUf6N|BLTnWwY4Tpc44hSXO|YYm= NU\0TmV2OTBxM{CvNVAxKM7:TR?= MYKxJIg> MUDpcohq[mm2ZYOgZo91cCCWV1XBT{1qdmS3Y3XkJJAyODBicILvZ4V{e2mwZx?= MmrvNlM2OjdzNUS=
HT29 MknySpVv[3Srb36gRZN{[Xl? NEPBV4cyOC9|MD:xNFAh|ryP M3vVdlEhcA>? MlKzbY5pcWKrdIOgWG5HNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJIFv\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= NYjtb|BTOjN3MkexOVQ>
MM.1S MoXaRZBweHSxc3nzJGF{e2G7 M1q0OlMxKML3TR?= MnrXN{Bp M3TIb4lv\HWlZYOgUW0h[2WubDDk[YF1cCCrbo\vcJZmeyCwZXPyc5Nqew>? NVvIbVdEOjN3MkexOVQ>
KMS-12-BM MYfBdI9xfG:|aYOgRZN{[Xl? NYfqdZJyOzBiwsXN NX\wU5ZEOyCq MULpcoR2[2W|IF3NJINmdGxiZHXheIghcW64b3z2[ZMhdmWlcn;zbZM> M1XiSVI{PTJ5MUW0
BAFs MYDGeY5kfGmxbjDBd5NigQ>? M2TvUVAvPS9zwrFOwG0> MUKyOEBp MV;pcohq[mm2czDUUmbPuS:GRWigbY5lfWOnZDDDXXAyQUFzwrD0doFve2O{aYD0dy=> MXOyN|Q5PTR3Nx?=
SP6.5 NXzqTZQ2TnWwY4Tpc44hSXO|YYm= NHmySFg2KM7:TR?= NUf0VVhyOiCq NHfCe3pl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? NFzUeW4zOzR2M{C4Oi=>
VUP M2POUGZ2dmO2aX;uJGF{e2G7 NUTvZWNpPSEQvF2= NX;VbnZuOiCq MYPk[YNz\WG|ZYRCpJRz[W6|bH;jZZRqd25ib3[gdFY2KGmwIITo[UBvfWOuZYXzxsA> NVrWc|F4OjN2NEOwPFY>
OCM1 NYX6R3BVTnWwY4Tpc44hSXO|YYm= NXfvbJF4PSEQvF2= MlnQNkBp Mon3[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh MkPnNlM1PDNyOE[=
OM431 MVzGeY5kfGmxbjDBd5NigQ>? M2DCOlUh|ryP NGPqelIzKGh? MYjk[YNz\WG|ZYRCpJRz[W6|bH;jZZRqd25ib3[gdFY2KGmwIITo[UBvfWOuZYXzxsA> Mn;yNlM1PDNyOE[=
SP6.5 M{jzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S2XVIvPS1{MDFOwG0> MnPiNlQhcMLi M1T5XmlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MknQNlM1PDNyOE[=
VUP NEHj[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\MdFYzNjVvMkCg{txO MnixNlQhcMLi M3\IPGlEPTB;NTFOwG0tKGW6aHnibZR{KHO2cn;u[{BidnSrLYDyc4xq\mW{YYTpeoUh\W[oZXP0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUKyN|Q1OzB6Nh?=
OCM1 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrmNk42NTJyIN88US=> NYnCTYRnOjRiaNMg MlvaTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{CxR|I{PDR|MEi2
OM431 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTqNk42NTJyIN88US=> MVmyOEBpyqB? MVXJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1vZdVI{PDR|MEi2
SP6.5 NIDmW3NCeG:ydH;zbZMhSXO|YYm= MXm1JO69VQ>? M4LQNVI1KGkEoB?= M{HxfYlv\HWlZYOgZZBweHSxc3nzxsA> MW[yN|Q1OzB6Nh?=
VUP MYjBdI9xfG:|aYOgRZN{[Xl? M{PYOVUh|ryP MUKyOEBpyqB? M1PKRolv\HWlZYOgZZBweHSxc3nzxsA> NXjaTIloOjN2NEOwPFY>
OCM1 MXzBdI9xfG:|aYOgRZN{[Xl? NFXmNIg2KM7:TR?= MmXWNlQhcMLi NHrPUZRqdmS3Y3XzJIFxd3C2b4Ppd:Kh M3fmbFI{PDR|MEi2
OM431 NEjOXItCeG:ydH;zbZMhSXO|YYm= NUfHPIR3PSEQvF2= MkLKNlQhcMLi NUjZZVQ6cW6mdXPld{BieG:ydH;zbZPDqA>? NYPuSpJ{OjN2NEOwPFY>
SP6.5 NEG5dWVHfW6ldHnvckBCe3OjeR?= NYe4PHo4PSEQvF2= MVOxNkBp MlyydoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NIeycYwzOzR2M{C4Oi=>
VUP MkPXSpVv[3Srb36gRZN{[Xl? MYm1JO69VQ>? M3XtOVEzKGh? NIPrUZdz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= MmP5NlM1PDNyOE[=
OCM1 NWXm[XB2TnWwY4Tpc44hSXO|YYm= MoLZOUDPxE1? MmnlNVIhcA>? M1rHNpJm\HWlZYOgeIhmKG2rZ4LheIlwdsLi NVnjc4hzOjN2NEOwPFY>
OM431 MnnZSpVv[3Srb36gRZN{[Xl? NEjQSHU2KM7:TR?= NInpNowyOiCq NHviS3dz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= M{HvOlI{PDR|MEi2
HBL-1  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1c3g{yqEQvF2= MonjNlQwPDhxN{KgbC=> NEXP[pZFVVOR NGD6UlR{dG:5czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NGXMR|AzOzR2MUezNC=>
RAW 264.7 M{fFbGZ2dmO2aX;uJGF{e2G7 M2P2TVIuOTVizszN M1u4O|EhcA>? NH7qNmVFVVOR NUnVO4tse3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? NVPHZXJJOjN2NEG3N|A>
IL-1R  NWjPVoxJTnWwY4Tpc44hSXO|YYm= NXHrWlN1Oi1zNTFOwG0> NIfuSYkyKGh? NF7VO4tFVVOR MX\zeZBxemW|c3XzJJRp\SCjY4TpeoF1cW:wIH;mJGlMUyCoYX3pcJkhdWWvYnXydy=> MkSxNlM1PDF5M{C=
RAW 264.7 NHfYe2dHfW6ldHnvckBCe3OjeR?= MoTkNVUh|ryP Mn7FNUBp MlfKSG1UVw>? NVvDcnR6e3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCjbnSgTm5M NYPnb3hiOjN2NEG3N|A>
IL-1R  MnrBSpVv[3Srb36gRZN{[Xl? M1ToclE2KM7:TR?= MlzENUBp M2D4VWROW09? NYjZeJhQe3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCjbnSgTm5M NVrpbo0xOjN2NEG3N|A>
U2OS M3rPZWZ2dmO2aX;uJGF{e2G7 MljnNVUh|ryP MmjSNUBp M{f5[mROW09? MUjwdoV3\W62czD0bIUhVFCVLTDvdkBKVC1zLYP0bY12dGG2ZXSg[o9zdWG2aX;uJI9nKEt4Mz3wWYIh[2ijaX7zxsA> NET4SZEzOzR2MUezNC=>
MT‐1  NWK4bI1LTnWwY4Tpc44hSXO|YYm= NX75U|VlQMLiwsXt Mn7kN{Bp MX3k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCy4pEQV3RCXDNiYX7kJJDjiJB2RVLQNS=> MYmyN|I4QDR5OR?=
MT‐2  M{TtcmZ2dmO2aX;uJGF{e2G7 MYK4xsDDvW1? MUmzJIg> MYHk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCy4pEQV3RCXDNiYX7kJJDjiJB2RVLQNS=> MlXnNlMzPzh2N{m=
MT‐1  NEjyeXRHfW6ldHnvckBCe3OjeR?= MVO4xsDDvW1? NU[xVoZOOyCq NH3mXmpl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUheDZ3IIP1ZpVvcXRib3[gUmbjiJEQulNCpC=> MUSyN|I4QDR5OR?=
MT‐2  MmLhSpVv[3Srb36gRZN{[Xl? NX\kbIVSQMLiwsXt Ml3sN{Bp NXmzfXBk\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKHB4NTDzeYJ2dmm2IH;mJG5H6oDSzsrCxsA> NGfOZ2EzOzJ5OES3PS=>
MCF-7  NI\LbIhHfW6ldHnvckBCe3OjeR?= MmXYNk42NTF3IN88US=> NUK5OWo1OC53IHi= MVjEUXNQ Mke4Z4F2e2W|IITo[UBoemGmdXHsJIxwe3Nib3[gZ4VtdCCjZHjld4lwdg>? M3fNbFI{ODl|MkK3
HaCaT  Mn:0SpVv[3Srb36gRZN{[Xl? NHm3Nlc2NjEEoN88US=> MXWxxsBpyqB? MVPheJRmdnWjdHXzJJRp\SCWQ1;IMYlv\HWlZXSgdJJw\HWldHnvckBw\iCLTD22xsA> MVuyN|A1OTF4OB?=
A549  M{LmdWZ2dmO2aX;uJGF{e2G7 NYn1c3hzOSCq MVzpcohq[mm2czDMWGEucW6mdXPl[EBUWC2DIH3SUmEheHKxZIXjeIlwdsLic3nncolncWOjboTsfS=> MWKyN|A{OTJzMx?=
OA chondrocytes  NVrvdWk2TnWwY4Tpc44hSXO|YYm= MnfDNVAh|ryP NXPRSnY4OSCq MmL0Zoxw[2u|IITo[UBCT0VvQmPBMYlv\HWlZXSg[4Vv\S:ycn;0[YlvKGW6cILld5Nqd25ib3[gS3JRPzhib4KgR29ZNTJiKIC8NE4xPSl? MXWyNlk5OjJ{OB?=
RAW264.7 NGL0fFlHfW6ldHnvckBCe3OjeR?= MVWxOUDPxE1? MoXKNVUuOTJyIH3pci=> M3;1N4Jtd2OtczD0bIUheHKxZIXjeIlwdiCxZjDOU{whWEeHMjygZY5lKFSQRj5OtS=> NWf6SIdTOjJ5NEW1NlM>
RAW264.7 NYDOWpg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILpdIY2NTNyIN88US=> MlXYNlQhcA>? MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVSyPFU3OjJ5NEW1NlM>
HBL6 MX3BdI9xfG:|aYOgRZN{[Xl? NHy0enAxNjVxNT:yOUDPxE1? Ml7lOk8zPCCq NH:3PHBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZY5lKGynZXHkd{B1dyCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= Ml7yNlIxPzR6MkC=
HT29  MUXGeY5kfGmxbjDBd5NigQ>? MkGzNU0yOCEQvF2= MWSxNOKhcA>? NVjO[FFucW6lcnXhd4V{KEiRLUGgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MonpNlE3OjB7NkS=
Ca9–22 M3rrO2Fxd3C2b4Ppd{BCe3OjeR?= NGS2OmcyOMLizszNxsA> Ml3XNUBp NYnV[nFV[2:vcHzleIVtgSCrbnjpZol1eyCDTFGtVGRVNWmwZIXj[YQh[XCxcITvd4l{ NIDiemwzOTF|OES4NC=>
Ca9–22 MYrGeY5kfGmxbjDBd5NigQ>? NFnRfVgyOMLizszNxsA> MWKxJIg> MYnjc41xdGW2ZXz5JIFjem:pYYTld{B1cGViQVzBMXBFXC2rbnT1Z4VlKEqQSzDhZ5RqfmG2aX;u MYqyNVE{QDR6MB?=
A-549 NXjrR3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xNOKh|ryPwrC= MYGyOE81QCCq M1WyVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz Ml7PNlA5PjZyNEO=
AP MUjGeY5kfGmxbjDBd5NigQ>? Moj5OU8yOCEQvF2= NHr2T2E1QCCq Ml:3[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWOyNFU6PjZ2NR?=
AQ1 NGK2dIxHfW6ldHnvckBCe3OjeR?= M3rtUVUwOTBizszN M{XuVVQ5KGh? NEnUdYlld3ewcnXneYxifGW|IITo[UBDSURicILveIVqdiCuZY\lcEBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGLqO5EzODV7Nk[0OS=>
AP MV7GeY5kfGmxbjDBd5NigQ>? NIjacHQzOCEQvF2= M1TlXlQwQCCq MoPQ[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NGXVZmMzODV7Nk[0OS=>
AQ1 MX3GeY5kfGmxbjDBd5NigQ>? Mo\nNlAh|ryP MVq0M|ghcA>? NUXkc5p[\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NF:0[3EzODV7Nk[0OS=>
THP-1 NVPBXooyTnWwY4Tpc44hSXO|YYm= NFvRUXk2yqEQvF5CpC=> MlvRNE42KGh? MojOZZR1\W63YYTld{B1cGViTGDTMYlv\HWlZXSgdE1K|rqEzsGgdJJwfGWrbjDifUA4OiV? MoS1NlA{ODl5MUi=
K562 NX7JN4J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyyMVMxKM7:TR?= MViyOEBp MoXMTWM2OD16IN88UUxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlnZNVk3PDZ6MEe=
Jurket NVziWXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD4OoUzNTNyIN88US=> Mn\CNlQhcA>? NFXBeZJKSzVyPUeuNUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVixPVY1PjhyNx?=
U937 M3PmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf5SoVWOi1|MDFOwG0> M1XPTlI1KGh? MluzTWM2OD1zMD61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NX3pe4pHOTl4NE[4NFc>
PBMC NF2wUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuyMVMxKM7:TR?= M1LlO|I1KGh? NYjhRmpPUUN3ME20NE4zKM7:TTygbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4TSc|E6PjR4OEC3
K562 NEDOTZpCeG:ydH;zbZMhSXO|YYm= MUiyMVIxyqEQvF5CpC=> MXyyOEBp NHP1VWZqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZZBweHSxc3nz MnXsNVk3PDZ6MEe=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID